![novamind 5 novamind 5](http://mindmappingsoftwareblog.com/wp-content/uploads/2011/09/novamind-5-mac-2-300px.jpg)
Ketamine administration in depressive disorders: a systematic review and meta-analysis. 1–46.įond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. Arylcyclohexamines (ketamine, phencyclidine, and analogues) In: Brent J, Burkhart K, Dargan P, Hatten B, Megarbane B, Palmer R, editors. Mechanisms of ketamine action as an antidepressant.
Novamind 5 series#
Overall, this novel, cross-diagnostic intervention warrants future research to further explore its appropriateness in a treatment setting.Īnxiety Case series Depression Feeding and eating disorders Ketamine Psychotherapy. This study suggests the potential utility of G-KAP as an adjunct to intensive, specialized ED treatment.
![novamind 5 novamind 5](https://dtncm7b86mywn.cloudfront.net/screenshot/b38b46a3.png)
Clinical observations and participant reports corroborated improvements in depression and anxiety symptoms, good tolerability of ketamine treatment, and practical implementation of the G-KAP protocol in a residential ED treatment center.
![novamind 5 novamind 5](https://media.paperblog.fr/i/262/2628744/novamind-5-cest-T-1.jpeg)
Dosing sessions were well tolerated, and no serious adverse events were reported. Four of the 5 participants experienced clinically significant improvements on the PHQ-9 score (i.e., change greater than 5) while 2 of the 5 participants experienced clinically significant improvements on the GAD-7 score (i.e., change greater than 4) from pre-dose to 24-h post-dose after the last ketamine session. Measures of anxiety (GAD-7) and depression (PHQ-9) were administered pre-dose, 4-h post-dose, and 24-h post dose. This study reports on five participants with a diagnosis of an ED and comorbid mood and anxiety disorders who received weekly intramuscular ketamine injections in a group setting over 4 weeks. Depression and anxiety outcome measures, safety/tolerability, patient satisfaction, and ease of implementation of group-based ketamine-assisted psychotherapy (G-KAP) delivered to patients in intensive residential eating disorder (ED) treatment were assessed.